ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler


ORIJINAL ARAŞTIRMA

Nöromusküler Hastalıklarda Aktivite Kısıtlanması ve Fonksiyonel Değerlendirme: Tersiyer Bir Merkez Sonuçları
Activity Limitation and Functional Assessment in Neuromuscular Diseases: Results of a Tertiary Center
Received Date : 25 Oct 2022
Accepted Date : 27 Jan 2023
Available Online : 09 Feb 2023
Doi: 10.31609/jpmrs.2022-94011 - Makale Dili: TR
J PMR Sci. 2023;26(2):199-205
ÖZET
Amaç: Bu çalışmada, nöromusküler hastalık tanısı alan hastalarda aktivite kısıtlanması ve fonksiyonel değerlendirilme sonuçlarının araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya nöromusküler hastalık tanılı, nöromusküler hastalıklar polikliniğinde takipli; 6-80 yaş aralığında, tıbbi durumu stabil hastalar dâhil edildi. Bu hastaların dosya bilgileri retrospektif olarak tarandı. Hastaların sosyodemografik verileri ve nöromusküler hastalığa ilişkin son geliş kontrol muayenelerinde kayıtlanmış klinik verileri tarandı ve kaydedildi. Fonksiyonel değerlendirme için Fonksiyonel Ambulasyon Skalası, Vignos ve Brooke Skalaları, kavrama ve sıkma gücü, bağımsız yürüme durumu ve 6 Dakika Yürüme Testi sonuçları kaydedildi. Aktivite kısıtlanmasının değerlendirilmesi için kayıtlanmış Activlim anketi sonuçları kullanıldı. Activlim total skoru ile yaş, Brooke, Vignos, Fonksiyonel Ambulasyon Skalası, kavrama, sıkma, 6 Dakika Yürüme Testi arasında korelasyon olup olmadığı araştırıldı. Bulgular: Çalışmaya 69 erişkin 22 çocuk olmak üzere toplam 91 hasta dâhil edildi. Ortalama yaş 31,1±18,7 idi. Hastaların %63,7’si bağımsız mobilize, %61,6’sında Fonksiyonel Ambulasyon Skalası skoru 3 ve altındaydı. Yüzde 57,2’sinde Vignos Skalası 4 ve altında, %68,1’inde Brooke Skalası 2 ve altındaydı. Activlim total skoru ile Fonksiyonel Ambulasyon Skalası, kavrama gücü, sıkma kavrama gücü ve 6 Dakika Yürüme Testi arasında pozitif korelasyon, Vignos ve Brooke Skalaları arasında negatif bir korelasyon saptandı. Ancak yaş ile Activlim total skoru arasında anlamlı bir korelasyon saptanmamıştır. Sonuç: Çalışmamızda, nöromusküler hastalıklarda aktivite kısıtlanması özellikle fonksiyonel durum, kavrama gücü, yürüme mesafesi ile korele bulunmuştur. Nöromusküler hastalıklarda fonksiyonel değerlendirme yanında aktivite kısıtlanması mutlaka değerlendirilmelidir.
ABSTRACT
Objective: The aim of this study was to investigate the results of functional and activity limitation assesments in patients diagnosed with neuromuscular disease. Material and Methods: Patients with a stable medical condition, aged 6-80 years, diagnosed with neuromuscular disease, followed in the neuromuscular diseases outpatient clinic, were included in the study. The data of these patients were scanned retrospectively. The sociodemographic data of the patients and the clinical data of the neuromuscular disease recorded at the final check-up examinations were scanned and recorded. Functional Ambulation Scale, Vignos and Brooke Scales, grip and pinch strength, independent walking status and 6 minute walking test results were recorded for functional assesment. Recorded Activlim survey results were used to assess activity limitation. It was also investigated whether there is a correlation between Activlim total score and age, Brooke, Vignos, Functional Ambulation Scale, grip and pinch strength, and six-minute walking tests. Results: A total of 91 patients, 69 adults and 22 children, were included in the study. The mean age was 31.1±18.7 years. 63.7% of the patients were independently mobilized, and 61.6% of them had a Functional Ambulation Scale score of 3 and below. Vignos Scale was 4 and below in 57.2%, Brooke Scale was 2 and below in 68.1% of the patients. A positive correlation was found between Activlim total score and Functional Ambulation Scale, grip strength, pinch grip strength and 6 min walking test, and a negative correlation was found between Vignos and Brooke Scales. However, no significant correlation was found between age and Activlim total score. Conclusion: In this study, activity limitation in neuromuscular diseases was found to be correlated with functional status, grip strength, and walking distance. In neuromuscular diseases, activity limitation should be evaluated in addition to functional evaluation.
REFERENCES
  1. Johnson LB, Florence JM, Abresch RT. Physical therapy evaluation and management in neuromuscular diseases. Phys Med Rehabil Clin N Am. 2012;23:633-51. [Crossref]  [PubMed] 
  2. Abresch RT, Han JJ, Carter GT. Rehabilitation management of neuromuscular disease: the role of exercise training. J Clin Neuromuscul Dis. 2009;11:7-21. [Crossref]  [PubMed] 
  3. Mendell JR, Florence J. Manual muscle testing. Muscle Nerve. 1990;13 Suppl:S16-20. [Crossref]  [PubMed] 
  4. Zupan A. Assessment of the functional abilities of the upper limbs in patients with neuromuscular diseases. Disabil Rehabil. 1996;18:69-75. [Crossref]  [PubMed] 
  5. Cook JD, Glass DS. Strength evaluation in neuromuscular disease. Neurol Clin. 1987;5:101-23. [Crossref]  [PubMed] 
  6. Bérard C, Payan C, Hodgkinson I, et al; MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15:463-70. [Crossref]  [PubMed] 
  7. Merkies IS, Schmitz PI, van der Meché FG, et al; Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2003;74:99-104. [Crossref]  [PubMed]  [PMC] 
  8. Vandervelde L, Van den Bergh PY, Goemans N, et al. ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord. 2007;17:459-69. [Crossref]  [PubMed] 
  9. Merkies IS, Hughes RA. The measurement of disease. J Neurol Neurosurg Psychiatry. 2010;81:943. [Crossref]  [PubMed] 
  10. Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired patients. Standards for outcome assessment. Phys Ther. 1986;66:1530-9. [Crossref]  [PubMed] 
  11. Harris MH, Holden MK, Cahalin LP, et al. Gait in older adults: a review of the literature with an emphasis toward achieving favorable clinical outcomes, part I. Clin Geriatrics. 2008:33-42. [Link] 
  12. Vignos PJ Jr, Spencer GE Jr, Archibald KC. Management of progressive muscular dystrophy in childhood. JAMA. 1963;184:89-96. [Crossref]  [PubMed] 
  13. Brooke MH, Griggs RC, Mendell JR, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4:186-97. [Crossref]  [PubMed] 
  14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-7. Erratum in: Am J Respir Crit Care Med. 2016;193:1185. [Crossref]  [PubMed] 
  15. Vandervelde L, Van den Bergh PY, Goemans N, et al. Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire. Neuromuscul Disord. 2009;19:99-103. [Crossref]  [PubMed] 
  16. Kılınç M, Öksüz Ç, Gökmen D, et al. Turkish Adaptation of ACTIVLIM questionnaire in neuromuscular diseases by Rasch analysis. Ergoterapi ve Rehabilitasyon Dergisi. 2019;7:135-44. [Crossref] 
  17. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995;74:S70-92. [Crossref]  [PubMed] 
  18. Eng JJ, Chu KS, Dawson AS, et al. Functional walk tests in individuals with stroke: relation to perceived exertion and myocardial exertion. Stroke. 2002;33:756-61. [Crossref]  [PubMed] 
  19. Li AM, Yin J, Au JT, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007;176:174-80. [Crossref]  [PubMed] 
  20. Prahm KP, Witting N, Vissing J. Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular disease. PLoS One. 2014;9:e114273. [Crossref]  [PubMed]  [PMC] 
  21. Lammers AE, Hislop AA, Flynn Y, et al. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child. 2008;93:464-8. [Crossref]  [PubMed] 
  22. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41:500-10. [Crossref]  [PubMed] 
  23. Vignos PJ Jr, Archibald KC. Maintenance of ambulation in childhood muscular dystrophy. J Chronic Dis. 1960;12:273-90. [Crossref]  [PubMed] 
  24. Wren TA, Bluml S, Tseng-Ong L, et al. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol. 2008;190:W8-12. [Crossref]  [PubMed] 
  25. Düger T, Yilmaz O, Aki E, et al. The environmental barriers of children with Muscular Dystrophies and its effect on mother's low back pain. Disabil Rehabil. 2003;25:1187-92. [Crossref]  [PubMed] 
  26. Uchikawa K, Liu M, Hanayama K, et al. Functional status and muscle strength in people with Duchenne muscular dystrophy living in the community. J Rehabil Med. 2004;36:124-9. [Crossref]  [PubMed] 
  27. Lue YJ, Chen SS. The strength and functional performance in patients with facioscapulohumeral muscular dystrophy. Kaohsiung J Med Sci. 2000;16:248-54. [PubMed] 
  28. Lue YJ, Chen SS. Strength and functional performance of patients with limb-girdle muscular dystrophy. Kaohsiung J Med Sci. 2000;16:83-90. [PubMed]